Based on these results, our study suggests that co-administration of FLT3 inhibitors with BCR::ABL1 targeted therapies can overcome TKI resistance and BP progression in FLT3+ CML patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.